NASDAQ:DCPHDeciphera Pharmaceuticals Stock Price, Forecast & News

Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DCPH shares have increased by 27.9% and is now trading at $56.80. View which stocks have been most impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) issued its quarterly earnings results on Tuesday, May, 5th. The company reported ($1.36) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.28) by $0.08. The company earned $0.06 million during the quarter, compared to the consensus estimate of $2.50 million. View Deciphera Pharmaceuticals' earnings history.

16 analysts have issued twelve-month price objectives for Deciphera Pharmaceuticals' stock. Their forecasts range from $42.00 to $91.00. On average, they anticipate Deciphera Pharmaceuticals' share price to reach $68.31 in the next year. This suggests a possible upside of 20.3% from the stock's current price. View analysts' price targets for Deciphera Pharmaceuticals.

Media stories about DCPH stock have trended negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Deciphera Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 3,520,000 shares, an increase of 12.1% from the June 15th total of 3,140,000 shares. Based on an average trading volume of 517,500 shares, the short-interest ratio is currently 6.8 days. Currently, 9.7% of the company's shares are sold short. View Deciphera Pharmaceuticals' Current Options Chain.

Some companies that are related to Deciphera Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), ACADIA Pharmaceuticals (ACAD), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Mylan (MYL), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR) and Ultragenyx Pharmaceutical (RARE). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include Ionis Pharmaceuticals (IONS), Allena Pharmaceuticals (ALNA), Viking Therapeutics (VKTX), GW Pharmaceuticals PLC- (GWPH), Immunomedics (IMMU), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), AbbVie (ABBV), Bausch Health Companies (BHC) and Cytokinetics (CYTK).

(DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DCPH stock can currently be purchased for approximately $56.80.

Deciphera Pharmaceuticals has a market capitalization of $3.17 billion and generates $25 million in revenue each year. The company earns $-192,260,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe.

The official website for Deciphera Pharmaceuticals is www.deciphera.com.

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]